A phase 1/2 study of chemoimmunotherapy with toll-like receptor 8 agonist motolimod (VTX-2337) + anti-PD-L1 antibody MEDI4736 in subjects with recurrent, platinum-resistant ovarian cancer, for whom pegylated liposomal doxorubicin is indicated. Here, TLR8 is linked to ovarian cancer.